Technical Articles

MOG (myelin oligodendrocyte glycoprotein) is a myelin self-antigen and a core target in multiple-sclerosis research. This article explains its biology, epitopes and experimental uses.

How recombinant MOG (1-125) underpins experimental autoimmune encephalomyelitis models and supports multiple-sclerosis and autoimmunity research workflows.

MOG (1-125) is the extracellular IgV domain of myelin oligodendrocyte glycoprotein. This article explains its truncation range, immunodominant epitopes, glycosylation effect, and the EAE induction workflow.

Interleukin-3 (IL-3), as a critical hematopoietic growth factor and inflammatory regulator, plays a pivotal role in the pathogenesis of multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE).

MBP (68-86) is the highly immunogenic core peptide segment of myelin basic protein, serving as the most representative autoantigen in the central nervous system and playing a critical role in the development and progression of demyelinating diseases such as multiple sclerosis.

Multiple sclerosis (MS) is a complex central nervous system disease that poses significant challenges to patients' lives. However, with continuous advancements in medical research, scientists have discovered numerous potential therapeutic targets, bringing new hope for overcoming this disease.

Multiple Sclerosis (MS) is a classic autoimmune disease whose pathological mechanisms are not yet fully understood. To further investigate and comprehend the pathogenesis of MS, researchers widely employ the Experimental Autoimmune Encephalomyelitis (EAE) animal model. In these models, Myelin Oligodendrocyte Glycoprotein (MOG) is utilized as an immunogen to induce autoimmune lesions, mimicking the progression of MS. This article reviews the establishment and characteristics of the MOG-induced EAE animal model, its applications in studying autoimmune diseases, and explores the potential role of this model in elucidating the pathophysiology of MS.